Ginkgo Bioworks, which is developing a platform for cell programming and biosecurity, has expanded its strategic partnership with Novo Nordisk under an agreement that initially is anticipated to run more than five years.    Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. The partners aim to improve the manufacturing of Novo Nordisk’s medicines for serious chronic diseases, including diabetes and obesity medications. The companies also...